9.81
+0.39(+4.14%)
Currency In USD
| Previous Close | 9.42 |
| Open | 9.55 |
| Day High | 10.32 |
| Day Low | 9.55 |
| 52-Week High | 24.15 |
| 52-Week Low | 7.96 |
| Volume | 9,402 |
| Average Volume | 22,940 |
| Market Cap | 49.48M |
| PE | -0.84 |
| EPS | -11.73 |
| Moving Average 50 Days | 9.73 |
| Moving Average 200 Days | 14.55 |
| Change | 0.39 |
If you invested $1000 in AlloVir, Inc. (ALVR) since IPO date, it would be worth $16.8 as of August 18, 2025 at a share price of $9.81. Whereas If you bought $1000 worth of AlloVir, Inc. (ALVR) shares 3 years ago, it would be worth $54.47 as of August 18, 2025 at a share price of $9.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Kalaris and AlloVir Announce Stockholder Approval of Merger
GlobeNewswire Inc.
Mar 12, 2025 8:01 PM GMT
Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the de
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
GlobeNewswire Inc.
Nov 08, 2024 11:00 AM GMT
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Inven